RANGER II SFA: By Boston Scientific
(A Clinical Trial for the treatment of peripheral artery disease in legs using drug coated Balloon)
This is a randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries.
TOBA II BTK: By Intact Vascular
(A Clinical Trial for New Peripheral Revascularization Treatment Option Below the Knee using TACK Endovascular System)
This is a prospective, multi-center study designed to investigate the safety and efficacy of the Tack Endovascular System in patients with peripheral artery disease (PAD) below the knee joint.
COPPER-A Study: By The Horizons International Peripheral Group
(A Clinical Trial for the treatment of peripheral artery disease in legs by using drug coated Catheter)
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal stenoses and occlusions.
PB1046-PT-CL-0003-P1.5: By PhaseBio Pharmaceuticals Inc.
(A Phase II Heart Failure Study in Patients with Reduced Ejection Fraction)
A Phase 2a study to assess the safety, tolerability and PK response and explore the PD response following 4 weeks of once weekly subcutaneous injections of PB1046 in adult subjects with stable heart failure with reduced Ejection Fraction.
TOBA II: By Intact Vascular
(A Clinical Trial for New Peripheral Revascularization Treatment Option using TACK Endovascular System)
This is a prospective, multi-center study designed to investigate the safety and efficacy of the Tack Endovascular System in patients with peripheral artery disease (PAD) above the knee.
(CREDENCE): By National Heart Lung and Blood Institute (NHLBI)
(Study to evaluate diagnostic procedures of a new onset coronary artery disease)
This study is to evaluate and compare the role of currently available diagnostic modalities in the treatment of new onset coronary artery disease.
COMMANDER HF Study: By Janssen
(Study to evaluate addition of a blood thinner Xarelto in current treatment regimen for Heart Failure Patients)
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with chronic heart failure and
significant coronary artery disease following a recent hospitalization for exacerbation (worsening) of heart failure. Site is currently enrolling patients in this study.
(PARAGON-HF): By Novartis
(Study to evaluate efficacy and safety of a new Heart Failure Drug Entresto in comparison to valsartan)
This study is to evaluate the efficacy and safety of valsartan/sacubitril (Entresto) compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction. Site is currently enrolling patients in this study.
ORBIT II-AF REGISTRY: By Janssen
(Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)
The primary objective of this study is to evaluate the safety of various oral anticoagulant agents in patients with atrial fibrillation, when these agents are administered as standard of care. This study is currently open for enrollment.
ANTELOPE REGISTRY: By TriReme
(Assessment to treat Complex Plaques in the Heart with a Balloon Catheter)
This is an observational Study collecting data on commercial cases in which the Glider PTCA Balloon Catheter is used in accordance with the instructions for use. This study is currently open for enrollment.
BIOFLOW-V: By Biotronik
(A Study to evaluate effectiveness and safety of a drug eluting stent to treat plaques in the blood vessels of the heart)
To assess the safety and efficacy of the Orsiro Sirolimus (Drug) Eluting Coronary Stent in the treatment of subjects with significant coronary artery disease compared to the Xience coronary stent system.
BIOHELIX-I: By Biotronik
(A Stent Study to treat coronary artery disease)
The BIOHELIX-I trial is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will evaluate the safety and performance of BIOTRONIK’s PRO-Kinetic Energy coronary stent system in patients with
symptomatic, ischemic heart disease. More than 300 patients will be enrolled in this study.
BIOFLEX-I: By Biotronik
(A Stent Study to treat peripheral artery disease)
The BIOFLEX-I is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will evaluate safety and performance of BIOTRONIK’s Astron and Astron Pulsar stents for the treatment of peripheral artery disease.
CANTOS Trial: By Novartis
(Use of anti inflammatory drug canakinumab to prevent future heart attack)
The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) will test whether reducing inflammation among men and women who have had a prior heart attack can reduce the risk of another cardiovascular event happening in the future. The enrollment is this study is permanently closed, site is currently conducting follow ups on already enrolled patients.
DPX-305: By Dipexium Pharmaceuticals Inc.
(An antibiotic Study to treat Diabetic Foot Ulcer)
To assess effectiveness and safety of topical antibiotic in adults with diabetic foot ulcers with mild infection)
(Palm Registry): By Regeneron
(Study to assess how current medical therapies are being prescribed in hyperlipidemia patients)
The PALM registry is a multicenter, observational registry aimed at evaluating how lipid management is implemented in current clinical practice.
TI PAD EVR Study: By Astrazeneca
(Study to evaluate effective role of blood thinners Brilinta vs. Aspirin in peripheral vascular disease after angioplasty)
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain. Site is currently enrolling patients in this study.
CELESTIAL Trial: By Biotronik
(An defibrillator (ICD) study to prevent life threatening arrhythmias)
This post market, multi-center study non randomized trial to confirm the long-term safety and reliability of the Linox Lead System as used with BIOTRONIK ICDs. The GALAXY registry will provide data to fully characterize ICD lead failures, from implant through 5 years. The enrollment is this study is permanently closed, site is currently conducting follow ups on already enrolled patients.
EUCLID Trial: By Astrazeneca
(Use of blood thinner ticagrelor vs. clopidogrel in peripheral artery disease population)
This particular clinical study is a double-blind study to compare a blood thinner Ticagrelor with clopidogrel in patients who have Peripheral Artery Disease. The primary endpoint is to determine if ticagrelor is effective in preventing the occurrence of a heart attack, stroke, hospitalization for unstable angina and possibly death in patients diagnosed with Peripheral artery disease. The enrollment is this study is permanently closed, site is currently conducting follow ups on already enrolled patients.
PROMISE Trial: By Duke
(PROspective Multicenter Imaging Study for Evaluation of Chest Pain)
This trial is launched to determine if an initial non-invasive anatomic imaging strategy with coronary CT angiography (CTA) will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease relative to an initial functional testing strategy (usual care).
BRIDGE Trial: By Duke
(Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for a Surgery)
The goal of the BRIDGE study is to establish an evidence-based standard-of-care for the large number of patients who require temporary interruption of warfarin because of an elective procedure or surgery.
DAPT Trial: By Harvard
(To determine benefits of 12 versus 30 months of dual antiplatelet therapy)
The DAPT Study was an independent, large-scale study in size and scope that was investigating the benefits of 12 versus 30 months of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents (DES).
Protocol 1160.128: By Boehringer Ingelheim
(Use of Pradaxa in Atrial Fibrillation)
The purpose of this trial was to develop a treatment strategy for patients who take Pradaxa for Atrial Fibrillation and present with gastrointestinal symptoms. The two strategies were Pradaxa, within 30 minutes after a meal vs. Pradaxa with pantoprazole (an antacid).
SAPPHIRE TRIAL: By Cordis
(Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy)
The primary objective of this study was to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease. The devices to be utilized are the Cordis PRECISE® Nitinol Stent Systems (5.5F and 6F) and the Cordis ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW).
MICCAT Trial: By Boehringer Ingelheim
(Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension)
This Study was to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient’s quality of life scores.
RE-LY Trial: By Boehringer Ingelheim
(Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate)
The primary objective of this trial was to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
ARISTOTLE Trial: By Bristol Myers Squibb
(Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)
The trial seeked to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.
AVALON Study: By Pfizer
(The Atorvastatin and Amlodipine in Patients With Elevated Lipids and Hypertension)
The purpose of this study was to demonstrate that amlodipine 5 mg administered once daily in combination with atorvastatin 10 mg is an effective treatment for concomitant hypertension/dyslipidemia and helping patients to achieve their guideline-mandated goals for both conditions.
A-Heft Trial: By Nitromed
(African American Heart Failure Trial)
A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.
TROPIC Study: By Kos
(The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication)
The purpose of this study was to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries.
Protocol 21-98-214-01: By Otsuka
(Cilostazol for peripheral artery disease)
Randomized, placebo-controlled study to assess the long-term effects of Pletal in patients with intermittent claudication secondary to peripheral arterial disease.
PERISCOPE Trial: By Takeda
(Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus)
This study was to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
Protocol 01-06-TL-OPI-536-003: By Takeda
(Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus)
The purpose of this study was to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
Protocol M05-749: By Abbott
(Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood)
The purpose of this study was to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
Protocol M05-758: By Abbott
(Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia)
The primary purpose of this study was to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
Protocol 1235.1: By Boehringer Ingelheim
(Telmisartan (Micardis) and Amlodipine (Norvasc) – Factorial Design Study for the Treatment of Hypertension)
This study was to demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pressure.
Protocol HRA 29-1274A: By Novartis
(Qualitative Interviews With Patients Diagnosed With Coronary Artery Disease or Acute Coronary Syndrome)
The purpose of this research study was to conduct interviews with people who have been diagnosed with Acute Coronary Syndrome (ACS) or Coronary Heart Disease (CHD) in order to better understand their experiences with these health conditions with their hospitalization for these conditions.
Protocol HRA 10-1365A: By Novartis
(Qualitative Interviews With Patients Diagnosed With Chronic Heart Failure)
The purpose of this research study was to conduct interviews with people who have been diagnosed with Chronic Heart Failure in order to better understand their experiences with these health conditions and to inquire about the appropriateness of an existing questionnaire.